Drug Trial Radar · NCT06068946
VK2735 for Weight Management Phase 2
Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
Aug 31, 2023
Primary completion
Feb 27, 2024
Study completion Apr 2, 2024
Sponsor
- Lead sponsor
- Viking Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.
Conditions
- Weight Loss
Interventions
VK2735Biological
VK2735 is a peptide GLP-1 and GIP dual agonist
PlaceboBiological
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent (relative) change from baseline to Week 13 in body weightTime frame: 13 weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Viking Clinical Site #119
Birmingham, Alabama
Viking Clinical Site #114
Long Beach, California
Viking Clinical Site #110
Los Angeles, California
Viking Clinical Site #113
Tustin, California
Viking Clinical Site #116
Clearwater, Florida
Viking Clinical Site #106
Clearwater, Florida
Viking Clinical Site #112
Jacksonville, Florida
Viking Clinical Site #105
Ocoee, Florida
Viking Clinical Site #107
Port Orange, Florida
Viking Clinical Site #104
Indianapolis, Indiana
Viking Clinical Site #103
Louisville, Kentucky
Viking Clinical Site #109
Marrero, Louisiana
Viking Clinical Site #102
Kansas City, Missouri
Viking Clinical Site #111
Butte, Montana
Viking Clinical Site #108
Knoxville, Tennessee
Viking Clinical Site #101
Austin, Texas
Viking Clinical Site #118
Austin, Texas
Viking Clinical Site #100
Phoenix, Texas
Viking Clinical Site #115
San Antonio, Texas
Viking Clinical Site #117
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.